Lepu Biopharma Co., Ltd.

SEHK:2157 Stock Report

Market Cap: HK$7.1b

Lepu Biopharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lepu Biopharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth33.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Feb 10

Lepu Biopharma Co., Ltd.'s (HKG:2157) Low P/S No Reason For Excitement

With a price-to-sales (or "P/S") ratio of 11.1x Lepu Biopharma Co., Ltd. ( HKG:2157 ) may be sending bullish signals at...
Analysis Article • Sep 22

Lepu Biopharma Co., Ltd. (HKG:2157) May Have Run Too Fast Too Soon With Recent 29% Price Plummet

The Lepu Biopharma Co., Ltd. ( HKG:2157 ) share price has softened a substantial 29% over the previous 30 days, handing...
Analysis Article • Aug 06

Optimistic Investors Push Lepu Biopharma Co., Ltd. (HKG:2157) Shares Up 92% But Growth Is Lacking

SEHK:2157 1 Year Share Price vs Fair Value Explore Lepu Biopharma's Fair Values from the Community and select yours...
Analysis Article • Jun 20

What Lepu Biopharma Co., Ltd.'s (HKG:2157) 30% Share Price Gain Is Not Telling You

Despite an already strong run, Lepu Biopharma Co., Ltd. ( HKG:2157 ) shares have been powering on, with a gain of 30...
Analysis Article • May 04

Lepu Biopharma Co., Ltd.'s (HKG:2157) 27% Price Boost Is Out Of Tune With Revenues

Lepu Biopharma Co., Ltd. ( HKG:2157 ) shares have continued their recent momentum with a 27% gain in the last month...
Analysis Article • Aug 23

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Jul 18

The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

The Lepu Biopharma Co., Ltd. ( HKG:2157 ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Jun 03

Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Lepu Biopharma Co., Ltd. ( HKG:2157 ) shares have retraced a considerable 27% in the last month, reversing a fair...
Analysis Article • Apr 15

Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Lepu Biopharma Co., Ltd. ( HKG:2157 ) shareholders would be excited to see that the share price has had a great month...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lepu Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2157 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025935261-131-12N/A
9/30/202581842-131-23N/A
6/30/2025700-177-130-35N/A
3/31/2025534-294-194-115N/A
12/31/2024368-411-258-196N/A
9/30/2024286-242-296-243N/A
6/30/2024205-73-333-290N/A
3/31/2024215-47-313-271N/A
12/31/2023225-22-292-251N/A
9/30/2023197-254-366-307N/A
6/30/2023169-487-440-364N/A
3/31/202392-588-518-422N/A
12/31/202216-689-596-481N/A
9/30/20228-766-617-471N/A
6/30/2022N/A-843-638-460N/A
3/31/2022N/A-927-740-541N/A
12/31/2021N/A-1,011-841-622N/A
12/31/2020N/A-582-734-423N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2157's forecast earnings growth is above the savings rate (3%).

Earnings vs Market: Insufficient data to determine if 2157's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2157's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2157's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2157's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2157's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/13 01:36
End of Day Share Price 2026/06/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lepu Biopharma Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lu MengHaitong International Research Limited
Hanyang HuangIndustrial Securities Co. Ltd.
Sean WuMorgan Stanley